Wagner Bowman Management Corp boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,721 shares of the medical research company’s stock after buying an additional 1 shares during the period. Wagner Bowman Management Corp’s holdings in Amgen were worth $261,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in Amgen during the second quarter valued at $383,036,000. Wellington Management Group LLP increased its stake in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares in the last quarter. Nordea Investment Management AB increased its stake in Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock valued at $870,171,000 after buying an additional 1,547,099 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in Amgen during the first quarter valued at $113,507,000. Finally, UBS Asset Management Americas Inc. increased its stake in Amgen by 12.4% in the first quarter. UBS Asset Management Americas Inc. now owns 3,712,647 shares of the medical research company’s stock valued at $556,636,000 after buying an additional 409,863 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 0.82% on Friday, hitting $166.81. 3,999,620 shares of the company traded hands. The stock’s 50-day moving average is $171.68 and its 200 day moving average is $161.02. The stock has a market cap of $124.83 billion, a PE ratio of 17.07 and a beta of 0.87. Amgen Inc. has a 12 month low of $138.06 and a 12 month high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same period last year, the business earned $2.57 EPS. Amgen’s revenue for the quarter was up 5.9% compared to the same quarter last year. Equities research analysts expect that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were given a dividend of $1.00 per share. This represents a $4.00 annualized dividend and a yield of 2.40%. The ex-dividend date was Monday, August 15th. Amgen’s payout ratio is currently 40.90%.
AMGN has been the subject of several research analyst reports. Vetr downgraded shares of Amgen from a “buy” rating to a “hold” rating and set a $159.50 price target for the company. in a research note on Tuesday, June 7th. Bank of America Corp. reaffirmed a “hold” rating and set a $182.00 price target on shares of Amgen in a research note on Wednesday, June 8th. BMO Capital Markets reaffirmed an “outperform” rating and set a $186.00 price target on shares of Amgen in a research note on Thursday, June 9th. Leerink Swann reaffirmed a “market perform” rating and set a $186.00 price target on shares of Amgen in a research note on Thursday, June 9th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $202.00 price target on shares of Amgen in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $185.06.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.